vScreenML v2.0: Improved Machine Learning Classification for Reducing False Positives in Structure-Based Virtual Screening
The enthusiastic adoption of make-on-demand chemical libraries for virtual screening has highlighted the need for methods that deliver improved hit-finding discovery rates. Traditional virtual screening methods are often inaccurate, with most compounds nominated in a virtual screen not engaging the intended target protein to any detectable extent. Emerging machine learning approaches have made significant progress in this regard, including our previously described tool vScreenML. The broad adoption of vScreenML was hindered by its challenging usability and dependencies on certain obsolete or proprietary software packages. Here, we introduce vScreenML 2.0 to address each of these limitations with a streamlined Python implementation. Through careful benchmarks, we show that vScreenML 2.0 outperforms other widely used tools for virtual screening hit discovery.
Authors
- Grigorii Andrianov (ORCID: https://orcid.org/0000-0001-5328-4738)
- John Karanicolas (ORCID: https://orcid.org/0000-0003-0300-726X)
- Emeline Haroldsen (ORCID: https://orcid.org/0009-0008-6785-4859)
Institutions
- Fox Chase Cancer Center (US)
- Kazan Federal University (RU)
- Temple University (US)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2024-11-18
- DOI
- https://doi.org/10.3390/ijms252212350
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- W. M. Keck Foundation
- National Computational Infrastructure
- National Institutes of Health
- National Cancer Institute
- National Institute of General Medical Sciences
- Office of Advanced Cyberinfrastructure